Intermediatebiotechnology

Stem Cells and Genetics

Overview

Stem cells self-renew and differentiate: totipotent (zygote), pluripotent (ESCs/iPSCs: any cell type), multipotent (hematopoietic: blood lineages), unipotent. Genetic circuits (Oct4/Sox2/Nanog in pluripotency; lineage master TFs in differentiation) control fate; niche signals maintain stemness. Applications: bone-marrow transplant (standard), emerging iPSC therapies, and disease modeling.

Learning objectives

  • Define potency levels with examples
  • Explain pluripotency transcription factor networks
  • Describe stem-cell niches
  • List clinical applications and challenges

The potency hierarchy

Totipotent: zygote/early blastomeres (whole organism + placenta). Pluripotent: embryonic stem cells, iPSCs (all body cell types, not placenta). Multipotent: hematopoietic stem cells (blood), neural stem cells. Unipotent: spermatogonial stem cells. Potency narrows as epigenetic marks accumulate.

Potency = developmental options

Each step down the hierarchy closes epigenetic doors.

Genetic control of pluripotency

Oct4, Sox2, Nanog form a self-reinforcing circuit activating pluripotency genes and repressing differentiation; Polycomb keeps lineage genes poised (bivalent domains). Differentiation = master TFs (MyoD for muscle, GATA1 for erythroid) collapsing the circuit toward one fate.

Yamanaka's shortcut

Oct4/Sox2/Klf4/c-Myc force the pluripotency circuit on in adult cells: iPSCs.

Niches

Stem cells live in microenvironments supplying maintenance signals: HSCs in bone-marrow niches (osteoblasts, CXCL12), intestinal crypts (Wnt from Paneth cells), hair follicles. Remove the niche signals and stem cells differentiate or die: identity is partly extrinsic.

Context is fate

A stem cell outside its niche loses stemness: transplantation must recreate or find niches.

Medicine: now and next

Now: hematopoietic stem-cell transplant for leukemias, immunodeficiencies, sickle cell (standard for decades). Next: iPSC-derived retinal cells (AMD trials), dopaminergic neurons (Parkinson's), pancreatic beta cells (diabetes), lab-grown blood. Challenges: tumorigenicity (c-Myc, residual pluripotent cells), immune rejection, cost.

First success was blood

Bone-marrow transplant (1950s-70s) was stem-cell therapy before the term existed.

Key points

  • Totipotent -> pluripotent -> multipotent -> unipotent: narrowing options
  • Oct4/Sox2/Nanog circuit maintains pluripotency; master TFs drive fates
  • Niches provide extrinsic maintenance signals
  • HSCT is standard; iPSC therapies for retina, Parkinson's, diabetes in trials

Common misconceptions

✗ Myth: Embryonic stem cells come from embryos destroyed for patients.

✓ Truth: ESC lines derive from surplus IVF blastocysts donated for research; iPSCs now avoid embryos entirely.

✗ Myth: Stem cells can become anything, anytime.

✓ Truth: Adult stem cells are multipotent (lineage-restricted); only pluripotent cells have broad potential, with tumor risk.

Practice questions

Q1. Pluripotent stem cells can become
  1. Only blood
  2. Any body cell type
  3. Only placenta
  4. Nothing
Answer: B.

All somatic lineages, but not extraembryonic tissue (that's totipotency).

Q2. The core pluripotency factors include
  1. Insulin and glucagon
  2. Oct4, Sox2, Nanog
  3. p53 and Rb
  4. Actin and myosin
Answer: B.

The self-reinforcing OSN circuit defines pluripotency.

Q3. The longest-established stem-cell therapy is
  1. iPSC retina
  2. Hematopoietic stem-cell transplantation
  3. Hair cloning
  4. Brain transplants
Answer: B.

Bone-marrow transplant: standard care since the 1970s-80s.

Click a question to reveal the answer and explanation.

Frequently asked questions

Why is c-Myc risky in iPSCs?

It's an oncogene: reactivation can transform; Myc-free reprogramming cocktails are preferred clinically.

What is the Hayflick limit's relevance?

Differentiated cells senesce; stem cells' telomerase lets them self-renew long-term.

How are iPSCs used in disease modeling?

Patient iPSCs differentiated into affected cell types (neurons, cardiomyocytes) reveal disease mechanisms and screen drugs.